Trump's Drug Price Plan Boosts Pfizer, Bayer Stocks
Americans are paying more for medicines than people in the rest of the world. Now, pharmaceutical giants like Bayer and Pfizer are in talks to lower drug prices, boosting their stock market prices and potentially benefiting from US President Donald Trump's plans.
Trump aims to launch a platform, 'trumprx.gov', to reduce drug prices. Pfizer, one of the world's largest drugmakers, is already negotiating a deal with the US government to lower prices. The talks have seen Pfizer's stock market price rise. Meanwhile, Bayer's stock market price has also increased, nearing the strong resistance level of 30 euros, as investors hope for similar benefits. Pharmaceutical companies may be exempt from duties for three years if they offer lower drug prices, making these negotiations attractive. However, no specific details about the Bayer team handling these negotiations have been disclosed.
With Americans paying more for medicines, Trump's plans to lower drug prices have sparked negotiations between the US government and pharmaceutical giants like Pfizer and Bayer. These talks have boosted the companies' stock market prices, with Bayer's approaching a significant resistance level. If successful, these negotiations could lead to lower drug prices for Americans and potential benefits for the involved companies.
Read also:
- Eric Dane Diagnosed with ALS, Advocates for ACT for ALS
- Deepwater Horizon Oil Spill: BP Faces Record-Breaking Settlement - Dubbed 'Largest Environmental Fine Ever Imposed'
- Meta Unveils Ray-Ban AR Display Sunglasses; TikTok Agrees to $200 Million Deal
- Historic downtown temples to receive restoration funds totaling over 25 million pesos
